Pure Cycle Corp
Change company Symbol lookup
Select an option...
PCYO Pure Cycle Corp
FBBPF Prologis Property Mexico SA de CV
NRZ New Residential Investment Corp
BOMN Boston Omaha Corp
GLD SPDR® Gold Shares
GIS General Mills Inc
GILD Gilead Sciences Inc
GGN GAMCO Global Gold, Natural Resources & Income Trust
GGN GAMCO Global Gold, Natural Resources & Income Trust
GEF Greif Inc
Go

Utilities : Water Utilities | Small Cap Blend
Company profile

Pure Cycle Corporation is an integrated water company that provides wholesale water and wastewater services. The Company provides its services to wholesale customers, which include industrial customers and local governmental entities that provide water and wastewater services to their end-use customers located in the Denver, Colorado metropolitan area. The Company is engaged in selling water service to customers, using water rights owned or controlled by the Company and developing infrastructure to divert, treat and distribute that water and collect, treat and reuse wastewater. The Company owns a portfolio of water rights located in the Denver, Colorado metropolitan area, Southeastern Colorado in the Arkansas River, and the Western Slope of Colorado in the Colorado River. The Company's Denver area assets include Rangeview Water, the Lowry Range Property, Sky Ranch and Arapahoe County Fairgrounds.

Closing Price
$9.79
Day's Change
-0.18 (-1.81%)
Bid
--
Ask
--
B/A Size
--
Day's High
10.07
Day's Low
9.61
Volume
(Light)
Volume:
37,425

10-day average volume:
73,661
37,425

Gilead takes over remdesivir distribution in the U.S.

2:26 pm ET October 1, 2020 (MarketWatch)
Print

Shares of Gilead Sciences Inc. (GILD) were down 0.3% in trading on Thursday after the drugmaker announced it is now in charge of distributing remdesivir, its COVID-19 treatment, as of Oct. 1. When the Food and Drug Administration (FDA) granted an emergency use authorization (http://www.marketwatch.com/story/how-gileads-remdesivir-became-the-leader-in-the-rush-to-find-a-treatment-for-covid-19-2020-05-01) to the drug in May, it stipulated (http://www.marketwatch.com/story/infectious-disease-doctors-ask-government-to-explain-how-it-decides-who-gets-gileads-remdesivir-2020-05-07) that the U.S. government would be responsible for distributing the medication to hospitals for a set period of time. The company said it has the manufacturing capacity to meet current demand for remdesivir in the U.S., and it will also reach that benchmark globally, sometime this month. AmerisourceBergen Corp. (ABC) will continue to be the sole distributor of remdesivir in the U.S. Its stock was down 1.6% in afternoon trading. Gilead had announced plans in August to pursue a full FDA approval of the drug. Gilead's stock is down 2.9% for the year, while the S&P 500 has gained 4.1%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 01, 2020 14:26 ET (18:26 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.